Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Synergistic effect of combinations of sulfamethoxazole, trimethoprim, and colistin against Pseudomonas maltophilia and Pseudomonas cepacia.

Literature DB >> 4143759

Synergistic effect of combinations of sulfamethoxazole, trimethoprim, and colistin against Pseudomonas maltophilia and Pseudomonas cepacia.

Abstract

Eighteen strains of Pseudomonas maltophilia and eight strains of P. cepacia were tested for susceptibility to sulfamethoxazole, trimethoprim, and colistin in different combinations. A synergistic effect was found against most of the strains.

Entities: Chemical Species

Mesh：

Substances：

Year: 1974 PMID： 4143759 PMCID： PMC444683 DOI： 10.1128/AAC.6.4.521

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

5 in total

1. Nonfermentative gram-negative bacteria encountered in clinical specimens.

Authors: G L Gilardi
Journal: Antonie Van Leeuwenhoek Date: 1973 Impact factor: 2.271

2. Antibiotic sensitivity testing. Report of an international collaborative study.

Authors: H M Ericsson; J C Sherris
Journal: Acta Pathol Microbiol Scand B Microbiol Immunol Date: 1971

3. Colonization and infection with Pseudomonas cepacia.

Authors: G M Ederer; J M Matsen
Journal: J Infect Dis Date: 1972-06 Impact factor: 5.226

4. Bacteremia with and without meningitis due to Yersinia enterocolitica, Edwardsiella tarda, Comamonas terrigena, and Pseudomonas maltophilia.

Authors: A C Sonnenwirth
Journal: Ann N Y Acad Sci Date: 1970-10-30 Impact factor: 5.691

5. In vitro sensitivity of isolates of Pseudomonas aeruginosa to carbenicillin, gentamicin, tobramycin, and some other antibiotics.

Authors: B Wretland; C E Nord; T Wadström
Journal: Scand J Infect Dis Date: 1974

5 in total

14 in total

Review 1. Principles of combination therapy.

Authors: S Levin; A A Harris
Journal: Bull N Y Acad Med Date: 1975-10

2. Prevalence of serotypes of Xanthomonas maltophilia from world-wide sources.

Authors: B Schable; D L Rhoden; W R Jarvis; J M Miller
Journal: Epidemiol Infect Date: 1992-04 Impact factor: 2.451

3. In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

Authors: N Khardori; A Reuben; B Rosenbaum; K Rolston; G P Bodey
Journal: Antimicrob Agents Chemother Date: 1990-08 Impact factor: 5.191

4. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors: S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal: Antimicrob Agents Chemother Date: 1994-03 Impact factor: 5.191

5. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia.

Authors: C Lewin; C Doherty; J Govan
Journal: Antimicrob Agents Chemother Date: 1993-01 Impact factor: 5.191

Synergistic effect of combinations of sulfamethoxazole, trimethoprim, and colistin against Pseudomonas maltophilia and Pseudomonas cepacia.

1. Nonfermentative gram-negative bacteria encountered in clinical specimens.

2. Antibiotic sensitivity testing. Report of an international collaborative study.

3. Colonization and infection with Pseudomonas cepacia.

4. Bacteremia with and without meningitis due to Yersinia enterocolitica, Edwardsiella tarda, Comamonas terrigena, and Pseudomonas maltophilia.

5. In vitro sensitivity of isolates of Pseudomonas aeruginosa to carbenicillin, gentamicin, tobramycin, and some other antibiotics.

Review 1. Principles of combination therapy.

2. Prevalence of serotypes of Xanthomonas maltophilia from world-wide sources.

3. In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

4. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

5. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia.

Review 6. The epidemiology of Pseudomonas cepacia in patients with cystic fibrosis.

7. Serological classification of Xanthomonas maltophilia (Pseudomonas maltophilia) based on heat-stable O antigens.

8. Fourteen-year survival of Pseudomonas cepacia in a salts solution preserved with benzalkonium chloride.

9. Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination.

10. Antibacterial activity of co-trimazine in vitro and in vivo.